← Oncology Approval Tracker

FDA DECISION ·

Enhertu + pertuzumab

fam-trastuzumab deruxtecan-nxki + pertuzumab · Daiichi Sankyo

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer (IHC 3+ or ISH-positive on an FDA-approved test).

LAMPGEN ANALYSIS

Why it matters

The approval brings a HER2-directed antibody–drug conjugate plus pertuzumab into first-line treatment of eligible HER2-positive advanced disease.

What research teams should watch

Confirm HER2 positivity and put pneumonitis reporting and cardiac surveillance into the first-line treatment workflow.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

HER2-selected breast cancer

PRIMARY RECORDS

Sources